Thomas Denize
Impact in
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
- Health Informatics top 5%
Papers in
- Oncology 15
- Cancer Immunotherapy and Biomarkers 9
- Lung Cancer Research Studies 4
-
- Renal cell carcinoma treatment 12
- Co-authors
- Sabina Signoretti (9 shared papers)Cécile Badoual (7 shared papers)Emily Walton (4 shared papers)Éric Tartour (4 shared papers)Jeffrey A. Golden (1 shared paper)Eliana Marostica (1 shared paper)Jérémy Augustin (4 shared papers)H. Mirghani (3 shared papers)
- Journals
- Clinical Cancer Research (5 papers)Cancer Cell (3 papers)Human Pathology (2 papers)Nature Communications (2 papers)Journal for ImmunoTherapy of Cancer (2 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Thomas Denize
34 papers receiving 1.7k citations
Thomas Denize's Hit Papers
Peers
Comparison fields: 5 of 93
- Cancer Research 278
- Health Informatics 29
- Oncology 480
- Pulmonary and Respiratory Medicine 516
- Immunology 239
Countries citing papers authored by Thomas Denize
This map shows the geographic impact of Thomas Denize's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Denize with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Denize more than expected).
Fields of papers citing papers by Thomas Denize
This network shows the impact of papers produced by Thomas Denize. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Denize. The network helps show where Thomas Denize may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Denize, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma Hit paper breakdown → | 2021 | 432 |
| 2 | Progressive immune dysfunction with advancing disease stage in renal cell carcinoma Hit paper breakdown → | 2021 | 357 |
| 3 | A pathology foundation model for cancer diagnosis and prognosis prediction Hit paper breakdown → | 2024 | 293 |
| 4 | 2022 | 85 | |
| 5 | 2021 | 52 | |
| 6 | 2018 | 51 | |
| 7 | 2023 | 47 | |
| 8 | 2018 | 32 | |
| 9 | 2022 | 32 | |
| 10 | 2022 | 27 | |
| 11 | 2023 | 26 | |
| 12 | 2023 | 25 | |
| 13 | 2023 | 23 | |
| 14 | 2021 | 22 | |
| 15 | 2020 | 21 | |
| 16 | 2025 | 21 | |
| 17 | 2023 | 20 | |
| 18 | 2021 | 17 | |
| 19 | 2022 | 17 | |
| 20 | 2018 | 15 |
About Thomas Denize
Thomas Denize is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Otorhinolaryngology and Molecular Biology, having authored 39 papers that have together received 1.7k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (12 papers), Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (4 papers), Lung Cancer Research Studies (4 papers), Head and Neck Cancer Studies (3 papers), RNA modifications and cancer (3 papers), Renal and related cancers (3 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). The work is most often cited by research in Cancer Research (278 citations), Health Informatics (29 citations), Oncology (480 citations), Pulmonary and Respiratory Medicine (516 citations) and Immunology (239 citations). Thomas Denize has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Sabina Signoretti, Cécile Badoual, Emily Walton, Éric Tartour, Jeffrey A. Golden, Eliana Marostica, Jérémy Augustin, H. Mirghani, Isaac S. Kohane and Kun‐Hsing Yu. Their work appears in journals such as Clinical Cancer Research, Cancer Cell, Human Pathology, Nature Communications and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.